Cav beta 2 Antibody: PerCP
CAT:
400-SMC-332D-PCP
Size:
100 µg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No










Cav beta 2 Antibody: PerCP
- Background: Cav Beat subunits are involved in the transport of the pore forming alpha1 subunit to the plasma membrane (1). They also shield an ER Retention signal on the alpha1 subunit, thereby guiding the pore-forming subunit to the target membrane (2, 3). They also determine the biophysical properties of the calcium channel (3).
- Description: Mouse Anti-Rat Cav beta 2 Monoclonal IgG1
- Specifications: Detects ~78 kDa. No cross reactivity against Cavβ1, Cavβ3, Cavβ4.
- Product Name Alternative: Cacnlb2 Antibody, cacnb2 Antibody, Voltage-dependent L-type calcium channel subunit beta-2 Antibody, CAB2 Antibody
- Synonyms: CavBeta2 Antibody, Clone N8b/1: PerCP
- CAS Number: 9007-83-4
- UNSPSC: 12352203
- Gene ID: 116600
- Swiss Prot: Q8VGC3
- Accession Number: NP_446303
- Cellular Locus: Cell Membrane | Sarcolemma
- Host: Mouse
- Species Reactivity: Human, Mouse, Rat
- Immunogen: Synthetic peptide amino acids 189-205 of rat CavBeta2
- Target: CavBeta2
- Clonality: Monoclonal
- Isotype: IgG1
- Clone: N8b/1 (Formerly sold as S8B-1)
- Conjugation: PerCP
- Validated Applications: WB, IHC, ICC/IF, ELISA
- Purification: Protein G Purified
- Limit Of Detection: 1 µg/ml of SMC-332 was sufficient for detection of Cavβ2 in 10 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody
- Concentration: 1 mg/ml
- Dilution: WB (1:1000), IHC (1:1000), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
- Weight: 0.1
- Buffer: 95.64mM Phosphate, 2.48mM MES and 2mM EDTA
- Precautions: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
- References & Citations: 1. Dolphin A.C. (2003) J Bioenerg. Biomembr. 35: 599-620. 2. Bichet D., et al. (2000) Neuron. 25: 177-190. 3. Xie M., et al. (2007) J Cell Biol. 178(3): 489-502.